Company intelligence / Profile preview
Koutif Therapeutics
Beachwood, Ohio, United Stateskoutiftherapeutics.com ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
Koutif Therapeutics develops first-in-class small molecule inhibitors targeting Fbxo3 to modulate inflammation by promoting degradation of pro-inflammatory proteins. Their lead compound, KT‑1002, received FDA IND clearance in early 2019 to begin Phase 1 trials for IBD. The company’s technology originates from discoveries at University of Pittsburgh and VA Medical Center. No published clinical results yet; Phase 1 will assess safety and pharmacokinetics.
- Therapeutic areas
- Gastroenterology
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive IP license from University of Pittsburgh and U.S. Department of Veterans Affairs
Beyond the preview
Go deeper on Koutif Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Koutif Therapeutics.